-
1 Comment
Wooridul Huebrain Limited is currently in a long term downtrend where the price is trading 24.0% below its 200 day moving average.
From a valuation standpoint, the stock is 59.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Wooridul Huebrain Limited's total revenue sank by 45.5% to $9B since the same quarter in the previous year.
Its net income has increased by 637.6% to $6B since the same quarter in the previous year.
Finally, its free cash flow grew by 215.7% to $5B since the same quarter in the previous year.
Based on the above factors, Wooridul Huebrain Limited gets an overall score of 3/5.
| Exchange | KO |
|---|---|
| CurrencyCode | KRW |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| ISIN | KR7118000009 |
| Market Cap | 52B |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.73 |
| Dividend Yield | None |
METACARE CO., Ltd. distributes pharmaceuticals and medical devices in South Korea. The company sells orthopedic medical devices and consumables; and provides pharmaceutical integration and professional logistics services. It is involved in investment advisory. The company was formerly known as SMEDI Co., Ltd. and changed its name to METACARE CO., Ltd. in August 2024. METACARE CO., Ltd. was founded in 2009 and is headquartered in Hwaseong-si, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 118000.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
